Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the Canaccord Genuity Musculoskeletal Conference on March 7, 2023, at 12:30 p.m. ET. A webcast of this presentation can be accessed through Vericel's Investor Relations website. The company specializes in advanced therapies for sports medicine and severe burn care, offering products like MACI®, an autologous scaffold for knee cartilage defects, and Epicel®, a permanent skin replacement for severe burns. Vericel also holds exclusive rights to NexoBrid® for burn treatment. For further details, visit the company's official website.

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 12:30 p.m. ET (9:30 a.m. PT) on Tuesday, March 7, 2023.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The Company markets two cell therapy products and one specialty biologic product in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2023 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com

FAQ

When is Nick Colangelo presenting at the Canaccord Genuity Musculoskeletal Conference for Vericel Corporation (VCEL)?

Nick Colangelo will present on March 7, 2023, at 12:30 p.m. ET.

Where can I find the webcast of Vericel Corporation's presentation at the conference?

The webcast will be available on the Investor Relations section of Vericel's website.

What products does Vericel Corporation (VCEL) offer for sports medicine and burn care?

Vericel offers MACI® for knee cartilage repair and Epicel® for skin replacement in severe burns.

What is NexoBrid® and how is it related to Vericel Corporation (VCEL)?

NexoBrid® is a biological orphan product for burn treatment, for which Vericel holds North American rights.